Recent investigations have converged on the intersection of GLP|GIP|glucagon receptor stimulant therapies and dopamine signaling. While GIP stimulators are increasingly employed for treating type 2 T2DM, their potential effects on reinforcement circuits, specifically influenced by dopamine networks, are attracting considerable attention. This re… Read More